A multi-parametric evaluation during anti-PD-1 therapies in patients with advanced melanoma can show changes in normal values for some immune cells in peripheral blood, such as T-cell subsets, B cells, and NK cells, which could provide valuable information on the efficacy of the immune treatment. This evidence concerns the gene PDCD1 and melanoma.